South Korea
· Delayed Price · Currency is KRW Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 157.56 billion. The enterprise value is 165.12 billion.
| Market Cap | 157.56B |
| Enterprise Value | 165.12B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Meta Biomed has 27.26 million shares outstanding. The number of shares has increased by 24.95% in one year.
| Current Share Class | 27.26M |
| Shares Outstanding | 27.26M |
| Shares Change (YoY) | +24.95% |
| Shares Change (QoQ) | +25.63% |
| Owned by Insiders (%) | 21.31% |
| Owned by Institutions (%) | 4.31% |
| Float | 21.45M |
Valuation Ratios
The trailing PE ratio is 9.16.
| PE Ratio | 9.16 |
| Forward PE | n/a |
| PS Ratio | 1.59 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | 11.05 |
| P/OCF Ratio | 7.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.18, with an EV/FCF ratio of 11.57.
| EV / Earnings | 7.37 |
| EV / Sales | 1.66 |
| EV / EBITDA | 7.18 |
| EV / EBIT | 9.17 |
| EV / FCF | 11.57 |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.20 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 2.43 |
| Debt / FCF | 3.92 |
| Interest Coverage | 4.44 |
Financial Efficiency
Return on equity (ROE) is 24.78% and return on invested capital (ROIC) is 7.52%.
| Return on Equity (ROE) | 24.78% |
| Return on Assets (ROA) | 6.58% |
| Return on Invested Capital (ROIC) | 7.52% |
| Return on Capital Employed (ROCE) | 17.41% |
| Revenue Per Employee | 344.56M |
| Profits Per Employee | 77.84M |
| Employee Count | 288 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.99 |
Taxes
In the past 12 months, Meta Biomed has paid 1.97 billion in taxes.
| Income Tax | 1.97B |
| Effective Tax Rate | 8.19% |
Stock Price Statistics
The stock price has increased by +24.89% in the last 52 weeks. The beta is 0.73, so Meta Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +24.89% |
| 50-Day Moving Average | 5,279.90 |
| 200-Day Moving Average | 4,300.20 |
| Relative Strength Index (RSI) | 55.48 |
| Average Volume (20 Days) | 1,157,238 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 99.23 billion and earned 22.42 billion in profits. Earnings per share was 637.11.
| Revenue | 99.23B |
| Gross Profit | 48.93B |
| Operating Income | 18.01B |
| Pretax Income | 24.09B |
| Net Income | 22.42B |
| EBITDA | 22.99B |
| EBIT | 18.01B |
| Earnings Per Share (EPS) | 637.11 |
Balance Sheet
The company has 51.00 billion in cash and 55.92 billion in debt, giving a net cash position of -4.92 billion or -180.32 per share.
| Cash & Cash Equivalents | 51.00B |
| Total Debt | 55.92B |
| Net Cash | -4.92B |
| Net Cash Per Share | -180.32 |
| Equity (Book Value) | 100.19B |
| Book Value Per Share | 4,273.04 |
| Working Capital | 15.32B |
Cash Flow
In the last 12 months, operating cash flow was 21.71 billion and capital expenditures -7.45 billion, giving a free cash flow of 14.27 billion.
| Operating Cash Flow | 21.71B |
| Capital Expenditures | -7.45B |
| Free Cash Flow | 14.27B |
| FCF Per Share | 523.31 |
Margins
Gross margin is 49.31%, with operating and profit margins of 18.15% and 22.59%.
| Gross Margin | 49.31% |
| Operating Margin | 18.15% |
| Pretax Margin | 24.28% |
| Profit Margin | 22.59% |
| EBITDA Margin | 23.17% |
| EBIT Margin | 18.15% |
| FCF Margin | 14.38% |
Dividends & Yields
This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.53%.
| Dividend Per Share | 30.00 |
| Dividend Yield | 0.53% |
| Dividend Growth (YoY) | 50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 3.06% |
| Buyback Yield | -24.95% |
| Shareholder Yield | -24.41% |
| Earnings Yield | 14.23% |
| FCF Yield | 9.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 23, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 2.14 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | 5 |